Indo Us Bio-Tech Intrinsic Value
Indo Us Bio-Tech intrinsic value. Indo Us Bio-Tech (INDOUS) median intrinsic value is ₹43.33 from 1 valuation models (range ₹43–₹43), vs current price ₹75.53 — -42.6% downside (Trading Above Calculated Value), margin of safety -74.3%. Read INDOUS ex-dividend dates for the complete payout history and dividend yield track record.
INDOUS Valuation Methods Summary — DCF, Graham Number & P/E
Indo Us Bio-Tech intrinsic value across 1 models vs current price ₹75.53 — upside/downside and value range per method. For current market price and key ratios, visit INDOUS stock price BSE.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹43.33 | ₹39.00 - ₹47.66 | -42.6% | Book Value/Share: ₹43.33, P/B: 1.0x |
INDOUS Intrinsic Value vs Market Price — All Valuation Models
Indo Us Bio-Tech fair value range ₹43–₹43 vs current market price ₹75.53 across 1 valuation models. Compare with INDOUS fair price to assess whether the stock is under or overvalued.
INDOUS Intrinsic Value Analysis — Undervalued or Overvalued?
Indo Us Bio-Tech median intrinsic value ₹43.33, current price ₹75.53 — Trading Above Calculated Value by 42.6%, margin of safety -74.3%.
What is the intrinsic value of INDOUS?
Based on our comprehensive analysis using 1 different valuation methods, the estimated intrinsic value of Indo Us Bio-Tech (INDOUS) is ₹43.33 (median value). With the current market price of ₹75.53, this represents a -42.6% variance from our estimated fair value.
The valuation range spans from ₹43.33 to ₹43.33, indicating ₹43.33 - ₹43.33.
Is INDOUS undervalued or overvalued?
Based on our multi-method analysis, Indo Us Bio-Tech (INDOUS) appears to be trading above calculated value by approximately 42.6%.
INDOUS Financial Health — Key Ratios vs Industry Benchmarks
Indo Us Bio-Tech financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 9.40 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
INDOUS Cash Flow Quality — Operating & Free Cash Flow
Indo Us Bio-Tech operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2022 | ₹3 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹0 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |
| March 2020 | ₹-1 Cr | ₹-2 Cr | Negative Cash Flow | 3/10 |